Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates;El papel de apixaban en la enfermedad tromboembólica venosa y arterial

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages 1199-1206

  Baillargeon, Jacques ^a   Kuo, Yong Fang ^a   Lin, Yu Li ^a   Wilkinson, Gregg S ^a   Goodwin, James S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Bisphosphonates; Older adults; Osteonecrosis; Osteoporosis

Indexed keywords

ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ELDERLY CARE; FACIAL BONE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; JAW OSTEONECROSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MORBIDITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; JAW DISEASES; MALE; MEDICARE; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 80053971389     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q239     Document Type: Article

References (34)

1. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. DOI 10.1056/NEJM02030897.
2. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
3. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22. DOI 10.1056/NEJMoa067312.
4. Food and Drug Administration. Early communication of an ongoing safety review on bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm070303.htm (accessed 2009 Dec 11).
5. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55. DOI 10.1056/NEJMoa010845.
6. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12. DOI 10.1097/01.ju.0000063820.94994.95.
7. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3. DOI 10.1111/j.1600-0714.2004.00269.x.
8. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. DOI 10.1016/j.joms.2004.02.004.
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. DOI 10.1016/S0278-2391(03)00720-1.
10. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63: 1567-75. DOI 10.1016/j.joms.2005.07.010.
11. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104:83-93. DOI 10.1002/cncr.21130
12. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20. DOI 10.1097/01.mlg.0000187398.51857.3c
13. Otto S, Abu-Id MH, Felker B, Warke PH, Becker ST, Kolk A. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence-a multi-centre study. J Craniomaxillofac Surg 2011;39:272-7.
14. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58. DOI 10.1016/j.clinthera.2007.08.008
15. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates. J Clin Oncol 2005;23:8580-7. DOI 10.1200/JCO.2005.02.8670.
17. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single experience in 303 patients. Br J Haematol 2006;134:620-3. DOI 10.1111/j.1365-2141.2006.06230.x.
18. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016-24. DOI 10.1093/jnci/djm025.
19. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9. DOI 10.1016/j.joms.2005.01.010.
20. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50(suppl 2):S4-13. DOI 10.1111/j.1834-7819.2005.tb00384.x.
21. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 2008;13:494-502. DOI 10.1634/theoncologist.2007-0200
22. Savarese DMF, Berenson JR. Bisphosphonates in breast, prostate, and other solid tumors. In: Basow DS, ed. UpToDate. Waltham, MA: UpTo-Date, 2011
23. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-9.
24. Rosen HN. Bisphosphonates in the management of osteoporosis in postmenopausal women. In: Basow DS, ed. UpToDate. Waltham, MA: Up-ToDate, 2011.
25. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90. DOI 10.3899/jrheum.080759
26. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. DOI 10.1016/j.joms.2006.10.061.
27. Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Fratzl P. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl 2006;103:A3078-80.
28. Jones JP. Osteonecrosis. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 13th ed. Baltimore, MD: Williams & Wilkins, 1997:1923-42.
29. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40(suppl 8):IV-26-35.
30. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27. DOI 10.1097/00005650-199801000-00004
31. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67. DOI 10.1016/S0895-4356(00)00256-0.
32. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer, 1997.
33. Allison PD. Survival analysis using the SAS System: a practical guide. Cary, NC: SAS Press, 1995.
34. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40.